Common Stock, $0.001 par value
- Symbol
- CATX
- Exchange
- NYSEAMER
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
Perspective Therapeutics, Inc.
CATXNYSE_AMERICANEQUITYCurrent
Other Events
Item 8.01 Other Events. On July 1, 2026, Perspective Therapeutics, Inc. updated its corporate presentation. A copy of the presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.
Company context
Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-generating isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging techniques that incorporate the same targeting moieties, creating an opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables visualization of the specific tumor and subsequent treatment, potentially improving efficacy and minimizing toxicity.
Current securities
Registered securities in this filing
Perspective Therapeutics, Inc. · 8-K · Filed 2026-07-01
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
On July 1, 2026, Perspective Therapeutics, Inc. updated its corporate presentation. A copy of the presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.
Filed exhibits (1)
EX-99.1 2 catx-ex99_1.htm EX-99.1 Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals Engineering the Alpha Advantage in Targeted Oncology Unlocking New Treatment Options Across Solid Tumors: Optimizing the Entire System Rapidly Advancing Best-in-Class Next Generation Radiopharmaceuticals Optimizing Structural Chemistry: Choosing The Right Isotope Not All ²¹²Pb Programs Are Created Equal Advancing a Theranostic Approach: Solid Tumors are an Attractive Market for Radiopharmaceuticals Expanding the Addressable Market Direct-to-Hospital Delivery through Integrated Isotope Production Daily Production at Regional Sites Ensures Supply of Ready-to-Administer Product Reaching the Largest Addressable Market with Regional Manufacturing Advancing a Diverse 212Pb-Based Oncology Portfolio SSTR2+ Neuroendocrine Tumors is a Large, Growing Market with Significant Unmet Need VMT-⍺-NET: Potential First-in-Class 212Pb-Radioligand Therapy Targeting SSTR2 Ongoing Phase 1/2a to Establish Broad Therapeutic Window for VMT-⍺-NET in NETs VMT-⍺-NET: Baseline Patient Characteristics in ASCO 2026 Data Analysis Patient Exposure and Follow-up with [212Pb]VMT-α-NET in AS…
Open exhibit ↗